Akston Biosciences Receives NIDDK Phase IIb Grant
Akston Biosciences received a Notice of Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) for $978,643 in first year funding for a Phase IIb SBIR grant. The funds will be used to support IND-enabling in vivo assay validation and large-animal, safety pharmacology studies for AKS-107, the company’s lead candidate for the prevention of Type 1 Diabetes.